An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054)

NCT06179875 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

143

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Eye Disease

Interventions

DRUG: Veligrotug

Sponsor

Viridian Therapeutics, Inc.